Anti-IL-18 [ABT-325 (A-794722.0; 2.5(E))]

Absolute Antibody

Anti-IL-18 [ABT-325 (A-794722.0; 2.5(E))]

7

The binding characterization of this antibody to human and cynomolgus monkey IL-18 was done using BIACORE assay. The binding affinity of the human IgG1 version was reported to be Kd=0.196 nM. This antibody can be used to immunoprecipitate human and cynomolgus monkey IL-18. This antibody neutralized both recombinant (KG-1 and RBA) and natural IL-18 (WBA) in an in vitro assay. The ability of this antibody to neutralize natural human IL-18-induced IFNgamma in an inflammatory environment in vivo, the severe combined immunodeficient (SCID) mouse model was used wherein human PBMCs were injected into the mouse and the cells were stimulated in vivo to produce human IL-18 (HuPBMC-SCID model). This antibody inhibited human IL-18-dependent human IFNgamma production in vivo with a clear dose-response by either route of administration. The binding of C1q to this antibody was determined using standard ELISA techniques (US20050100965). This antibody was used in the generation of a dual variable domain immunoglobulin (DVD-Ig) in combination with anti-IL-12 antibody for therapeutic use for targeting disease where multiple mediators contribute to overall disease pathogenesis (PMID: 17934452).

Flow Cytometry, ImmunoPrecipitation, ELISA, Neutralisation/Blocking

IP; ELISA; FC; neutralize

Research Use Only

Monoclonal

ABT-325 (A-794722.0; 2.5(E))

IL18

interleukin 18

iboctadekin; IFN-gamma-inducing factor; IGIF; IL-1 gamma; IL-18; IL1F4; IL-1g; interleukin 18 (interferon-gamma-inducing factor); interleukin-1 gamma; interleukin-18

Mouse

IgG2b

Interleukin-18

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.

Human, cynomolgus monkey

The original antibody was generated by immunizing transgenic Xenomouse with human IL-18 in phosphate-buffered saline.

-20°C,2°C to 8°C

12352203